Targeting Cancer with Tiny MoS2 Flowers and Enhanced Cellulose

SDG 3_Good Heath and Well-Being

Background

Cancer, a disease characterized by the uncontrolled proliferation of abnormal cells, necessitates the development of innovative therapeutic strategies. The development of nanocomposite-based therapies has gained significant attention in cancer treatment due to their targeted efficacy and reduced systemic toxicity. This study focuses on the synthesis of amino cellulose (AC) derivatives, their functionalization with molybdenum disulfide (MoS2), and their potential for application in cancer therapeutics.

Objective of the Research

The primary objective of this study was to modify microcrystalline cellulose (MCC) into amino cellulose derivatives and utilize them as a supporting material for the development of MoS2 nanocomposites. These nanocomposites were then investigated for their effectiveness against skin and breast cancer cell lines.

Research Gap in the Current Study

Despite the advancements in nanotechnology for cancer treatment, challenges such as poor selectivity, biocompatibility, and controlled degradation remain significant. Existing drug carriers often exhibit limitations in their ability to specifically target cancer cells without affecting normal fibroblast cells. This study aims to address these gaps by developing biocompatible AC-MoS2 nanocomposites with improved selectivity and efficacy.

Figure 1: MoS₂-Cellulose Nanocomposites for Cancer Therapy: A Synthesis Scheme
Figure 1: MoS₂-Cellulose Nanocomposites for Cancer Therapy: A Synthesis Scheme

Novelty of Research

This research introduces three novel amino cellulose derivatives: 6-deoxy-6-hydrazide cellulose (C-Hyd), 6-deoxy-6-(N,N-diethyl)amine cellulose (C-DEA), and 6-deoxy-6-diethyltriamine cellulose (C-DETA). These derivatives were synthesized through a two-step process involving MCC tosylation and subsequent functionalization. The modified cellulose was then used as a matrix for MoS2 adsorption, forming a nanocomposite with enhanced properties for cancer treatment.

Contribution of NUST to Research

This research was conducted with contributions from NUST, with support from faculty members and research teams specializing in nanotechnology and biomedical applications. The study was led by the Principal Investigator (PI) along with dedicated team members working on the synthesis, characterization, and biological evaluation of the nanocomposites.

Potential Benefits of Research

The development of AC-MoS2 nanocomposites presents a promising strategy for improving cancer treatment by offering:

  • Enhanced selectivity towards cancer cells
  • Biodegradability and controlled release properties
  • Reduced toxicity towards normal fibroblast cells These findings suggest that AC-MoS2 nanocomposites could serve as effective candidates for targeted skin and breast cancer therapy.

Key Characterization and Results

  • FTIR and 1H-NMR Spectroscopy confirmed the presence of NH moieties and successful MoS2 adsorption.
  • XRD and SEM–EDS Analyses verified the crystalline structure and morphology of the nanocomposites.
  • Swelling and Degradation Studies demonstrated stability and controlled degradation rates of the AC-MoS2 nanocomposites.
  • Cytotoxicity Studies using Presto blue and LIVE/DEAD staining revealed selective toxicity against cancer cell lines (B16F10, MDA-MB-231, and MCF-7), while maintaining biocompatibility with NIH3T3 fibroblast cells.

Research Findings and Adaptability

The findings indicate that AC-based MoS2 nanocomposites exhibit potential as a selective and biocompatible anticancer agent. Their adaptability allows for further modifications and potential applications in personalized medicine and targeted drug delivery.

Areas for Collaboration and Conclusion

This study opens avenues for collaboration in the fields of:

  • Advanced nanomaterial synthesis for biomedical applications
  • Clinical research for validating AC-MoS2 nanocomposites in cancer therapy
  • Drug delivery system optimization for improved targeting and efficacy

Funding Acknowledgement

This research was supported by HEC Pakistan, contributing to advancements in nanomedicine and cancer therapeutics.

Acknowledgement

We extend our gratitude to NUST, our research team, and supporting institutions for their valuable contributions and technical support in this study.


The author is a Professor, at School of Natural Sciences (SNS), National University of Sciences and Technology (NUST), Islamabad. He can be reached at [email protected].

Research Profile: https://bit.ly/4jpx8xA

Dr Mudassir Iqbal SNS, NUST
Dr Mudassir Iqbal SNS, NUST

Loading

Leave a Reply

Your email address will not be published. Required fields are marked *